MedTrace Logo

Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia

NCT04380376 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-05-12

No results posted yet for this study

Summary

This single-center, prospective, open-label, comparator study, blind for central accessor evaluates the efficacy, safety of inhalations of low-doses of melphalan in patients with pneumonia with confirmed or suspected COVID-19. All patients will receive 0,1 mg of melphalan in 7-10 daily inhalations 1 time per day.

Conditions

Interventions

DRUG

Melphalan

Inhalations with low doses of Melphalan for 7-10 consequent days

OTHER

Standard of care

the patients will receive only SOC (standard of care) treatment

Sponsors & Collaborators

  • Medsi Clinic #1, Moscow

    collaborator OTHER

  • Moscow State University of Medicine and Dentistry

    collaborator OTHER

  • Federal State Budgetary Institution, Pulmonology Scientific Research Institute

    lead OTHER_GOV

Principal Investigators

  • Kirill A Zykov, Prof · Federal State Budgetary Institution, Pulmonology Scientific Research Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-30
Primary Completion
2020-10-30
Completion
2020-10-30

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04380376 on ClinicalTrials.gov